文献速递淋巴瘤造血干细胞移植与细胞治疗

大剂量阿糖胞苷与自体干细胞移植治疗套细胞淋巴瘤:欧洲套细胞淋巴瘤网络随机MCL Younger试验长期随访

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
PubMed 文献 · J Clin Oncol · 2022-12-05

欧洲MCL网络2004年启动的随机开放标签III期MCL Younger试验,比较R-CHOP/R-DHAP诱导后含大剂量阿糖胞苷的清髓性放化疗联合自体干细胞移植与R-CHOP联合标准清髓性放化疗及自体干细胞移植。中位随访10.6年,R-DHAP组至治疗失败时间仍显著优于R-CHOP组(中位8.4 vs 3.9年,P=0.038,HR 0.59)。

要点

  • R-DHAP组至治疗失败时间中位8.4年,R-CHOP组中位3.9年,HR 0.59,P=0.038
  • R-DHAP组中位OS未达到,R-CHOP组中位OS 11.3年,未校正HR 0.80(95%CI 0.61-1.06),P=0.12
  • 10年时第二血液系统恶性肿瘤发生率R-DHAP组4.5% vs R-CHOP组1.4%

核心结论

  • 长期成熟数据证实R-DHAP方案较R-CHOP方案显著延长至治疗失败时间,并首次显示总生存改善。
  • 部分套细胞淋巴瘤患者可能被治愈。

研究设计与样本

  • 欧洲套细胞淋巴瘤网络2004年发起的随机开放标签III期MCL Younger试验,一线治疗晚期套细胞淋巴瘤、年龄<66岁患者。
  • R-DHAP组:交替R-CHOP/R-DHAP诱导后,行含大剂量阿糖胞苷的清髓性放化疗预处理及自体外周血干细胞移植。
  • R-CHOP组:R-CHOP联合标准清髓性放化疗及自体干细胞移植。

主要发现

  • 中位随访10.6年,至治疗失败时间R-DHAP组中位8.4年 vs R-CHOP组中位3.9年,5年/10年无治疗失败率64%/46% vs 41%/25%,P=0.038,HR 0.59。
  • 中位总生存R-DHAP组未达到 vs R-CHOP组11.3年,5年/10年总生存率76%/60% vs 69%/55%,P=0.12。
  • 未校正总生存HR 0.80(95%CI 0.61-1.06),P=0.12;校正MIPI后HR 0.74(95%CI 0.56-0.98),P=0.038;校正MIPI-c后HR 0.60(95%CI 0.41-0.87),P=0.0066。
  • 10年时第二血液系统恶性肿瘤发生率R-DHAP组4.5% vs R-CHOP组1.4%,R-DHAP组有升高趋势。

关键数值与推荐

  • 至治疗失败时间:R-DHAP组中位8.4年 vs R-CHOP组中位3.9年,5年/10年无治疗失败率64%/46% vs 41%/25%,P=0.038,HR 0.59。
  • 总生存:R-DHAP组中位未达到 vs R-CHOP组中位11.3年,5年/10年总生存率76%/60% vs 69%/55%,P=0.12。
  • 未校正总生存HR 0.80(95%CI 0.61-1.06),P=0.12。
  • 校正MIPI后总生存HR 0.74(95%CI 0.56-0.98),P=0.038。
  • 校正MIPI-c后总生存HR 0.60(95%CI 0.41-0.87),P=0.0066。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In 2004, the European Mantle Cell Lymphoma (MCL) Network initiated the randomized open-label, phase III MCL Younger trial for first-line treatment of patients with advanced-stage MCL, age < 66 years, comparing an alternating rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone/rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (R-CHOP/R-DHAP) induction followed by high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous peripheral blood stem-cell transplantation (R-DHAP arm) to R-CHOP with standard myeloablative radiochemotherapy and autologous stem-cell transplantation (R-CHOP arm). After a median follow-up of 10.6 years, the time to treatment failure was still significantly improved in the R-DHAP versus R-CHOP arms (medians 8.4 v 3.9 years, 5-/10-year rates 64%/46% v 41%/25%, P = .038, hazard ratio, 0.59). Median overall survival (OS) was not reached in the R-DHAP arm versus 11.3 years in R-CHOP arm (5-/10-year rates, 76%/60% v 69%/55%, P = .12). The unadjusted OS hazard ratios (0.80 [95% CI, 0.61 to 1.06], P = .12) reached significance when adjusted for Mantle Cell Lymphoma International Prognostic Index (MIPI) and MIPI + Ki-67 (MIPI-c) (0.74; 95% CI, 0.56 to 0.98; P = .038 and .60; 95% CI, 0.41 to 0.87; P = .0066). The incidence of secondary hematologic malignancies tended to be higher in the R-DHAP arm (4.5% v 1.4% at 10 years). With mature long-term data, we confirm the previously observed substantially prolonged time to treatment failure and, for the first time to our knowledge, show an improvement of OS. Some patients with MCL may be cured.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hermine O, Jiang L, Walewski J, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2022. PMID: 36469833. doi:10.1200/JCO.22.01780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。